AbbVie eyes Humira matching move into psoriatic arthritis for immunology follow-up Skyrizi
Pharma borg AbbVie hasn’t had many roadblocks on its path to dominance with megablockbuster Humira regularly topping pharma’s bestseller list. But Humira’s days on top are numbered, and AbbVie is making the case for newer immunology meds like IL-23 Skyrizi to help take the sting out of a costly 2023 patent cliff.
Helping that cause, Skyrizi bested placebo in terms of reducing psoriatic arthritis patients’ symptoms from baseline after six months of treatment, according to data from two Phase III trials unveiled Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.